Integra LifeSciences (IART) Bank of America Global Healthcare Conference 2026 summary

Leadership transition and strategic focus

• CEO transition to Stuart, who is now both Chairman and CEO, with continued focus on transformation and operational capability improvements.

• Emphasis on accelerating commercial strategy and growth, especially in neurosurgery, tissue reconstruction, and ENT markets.

• No change in core market focus, with a $9 billion total addressable market and strong competitive positioning.

Operational improvements and performance metrics

• Q1 results exceeded revenue and EPS guidance, reflecting transformation progress.

• Reduced supply disruptions and improved supply chain visibility through a control tower dashboard.

• Yield improvements and fewer regulatory audit observations signal operational stability.

• Cash flow improved meaningfully in Q1, with expectations for continued progress.

Sales force and commercial strategy

• No near-term expansion of the sales force; focus on optimizing existing team and leveraging strong surgeon relationships.

• Growth to be driven by bringing products back to market, portfolio expansion, and adapting to reimbursement changes.

• Use of analytical tools to enhance commercial efficiency.